EDSA · Edesa Biotech, Inc.
$2.77
+0.01 (+0.36%)
At close · Oct 23
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company’s ability to continue as a going concern is dependent on obtaining additional funding through financings, other strategic activities as well as via grants, to fund the development of its drug candidates. There can be no assurance that the Company will be successful in raising the necessary financing. These conditions indicate the existence of a material uncertainty that may cast substantial doubt about the Company’s ability to continue as a going concern.”View the 10-Q filed Aug 13, 2026
Market Cap
$26.71M
Shares
9.64M
Volume · Oct 23
18.56K
Avg daily vol (3M)
60.35K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.77
Open$2.71
Day$2.67–2.92
52W close$0.80–18.28
Avg vol 30d43K
Short int204K · 2.1% float · 4.8d
Short vol57%
Last earningsFeb 16, 2021
DataJan 2020–Oct 2026
Filing10-Q · Aug 13
Up next
filed Aug 13, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$0
Trailing 12 months
Net income (TTM)
−$14.10M
Trailing 12 months
Revenue growth YoY
-100.0%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$10.30M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+29.9%
Year over year · more shares
Price change (1Y)
+3.0%
Trailing year
Short interest
2.1%
Latest settlement · 4.8 days to cover
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Weak
Sentiment
Bullish
Fundamentals
Poor
Quant / Vol
Very High
Market backdrop
VIX 19.5 · elevated
Equity put/call 0.67
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−51%
below
Price vs 50-day avg
−32%
below
RSI (14)
33
neutral
MACD trend
Negative
52-week position
11%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−31%
trailing
6-month return
−83%
trailing
YTD return
+95%
this year
Relative strength
−89%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $4 › 200d $6 — 200d above 50d
Institutional flow
Accumulating
2 of 33 funds reported for Sep 30 · net +2 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
2.11% of float · ▼ -7.0% MoM · 4.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
33 holders — near 3-yr high, broad support
Squeeze score
42
elevated · 0–100
Fundamentals
Revenue growth
−100%
Y/Y
EPS growth
−58%
Y/Y
Free cash flow
$-7.3M
Quant / Vol
risk profile
Volatility
196%
annualized · 1-yr
Max drawdown
−86%
past year
ATR
11.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−51%
Bearish
Price vs 50-day avg
−32%
Bearish
RSI (14)
33
Neutral
MACD trend
Negative
Bearish
52-week position
11%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $4 › 200d $6 — 200d above 50d
Institutional flow
Accumulating
2 of 33 funds reported for Sep 30 · net +2 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
2.11% of float · ▼ -7.0% MoM · 4.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
33 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1
Now $3 · 11%
Range high $18
vs 200-day avg -51%
vs 50-day avg -32%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
EDSA
this stock
Edesa Biotech, Inc.
|
$26.71M | +95.1% | -100.0% | — | 2.1% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$132.80B | +15.6% | +46.2% | 30.5 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$82.88B | +4.3% | +20.8% | 19.9 | 2.1% |
|
MRNA
Moderna, Inc.
|
$79.89B | +578.5% | +4.3% | — | 7.7% |
|
CSLLY
Csl Ltd
|
$66.42B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
SEC Filings
Latest
8-K
- Filed
- Oct 23, 2026
- This year
- 18
Edesa Biotech, Inc.'s Board raised annual base salaries for Dr. Pardeep Nijhawan to $657,423, Dr. Michael Brooks to $591,681, and Peter Weiler to $525,938, retroactive to July 1, 2026. Dr. Nijhawan will continue receiving 90% of monthly base salary in fully vested restricted share units.
ViewEarnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| EDSA | +7.8% | -30.9% | -82.8% | -34.2% | +95.1% |
| SPY | -0.4% | -1.5% | +5.8% | -0.4% | +11.5% |
| vs SPY | +8.2% | -29.4% | -88.7% | -33.9% | +83.6% |